Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)
about
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionProtecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infantsAge-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adultsPharmacokinetics of tenofovir during pregnancy and postpartum.Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS.Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Pharmacokinetic considerations in the use of antivirals in neonates.Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.British HIV Association guidelines for the management of HIV infection in pregnant women 2012
P2860
Q28481276-B28D1069-D2F5-4057-8D09-DFF17D2B8DFCQ34429204-B95B7ECE-E701-4D8E-8A8D-280D6159341DQ35363649-5FEA2679-0960-4109-8D23-72416B3C5A43Q35598502-FF838D9C-A4F7-4B48-966E-F583CB27DCB5Q36650454-BFFA5E10-8110-4C89-A3EE-D8CA7D91BB50Q36888597-BB2EAFE5-ABDA-49ED-A532-226BCCFA214EQ37203867-617171B6-BC2B-4583-B02D-8C46205DD055Q37210864-2E94B9E1-818C-4435-8A0D-84B5EC049D3DQ37347434-6902B28C-8867-4927-8345-9B1C5388338DQ37551251-2A38E9A1-5D1E-49AF-8783-4421A59F74C7Q38260025-498EF159-354A-4CAC-8451-D69B1DB84C97Q38325427-DFD26255-C920-4435-A521-03DFDA982371Q38624965-059A1ABF-3F4A-49ED-A05C-2BB381BF713CQ38909409-9F748B86-78BC-491E-8E20-03B539771BC2Q39434360-0DC41E8F-D4C6-495F-B8C4-D2A08EAC746FQ57076282-F4A8D4E1-1BFF-43B5-8A1D-F5CBE45716B0
P2860
Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Plasma and intracellular tenof ...... ate (ANRS 12109 trial, step 2)
@ast
Plasma and intracellular tenof ...... ate (ANRS 12109 trial, step 2)
@en
type
label
Plasma and intracellular tenof ...... ate (ANRS 12109 trial, step 2)
@ast
Plasma and intracellular tenof ...... ate (ANRS 12109 trial, step 2)
@en
prefLabel
Plasma and intracellular tenof ...... ate (ANRS 12109 trial, step 2)
@ast
Plasma and intracellular tenof ...... ate (ANRS 12109 trial, step 2)
@en
P2093
P2860
P50
P356
P1476
Plasma and intracellular tenof ...... ate (ANRS 12109 trial, step 2)
@en
P2093
Alain Pruvost
Didier K Ekouévi
Divine Avit
Déborah Hirt
Elise Arrivé
James McIntyre
Jean-Marc Tréluyer
Leakhena Say
Mandisa Nyati
P2860
P304
P356
10.1128/AAC.01377-10
P407
P577
2011-04-04T00:00:00Z